These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23602668)

  • 1. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.
    Yang CF; Wang CK; Malkin E; Schickli JH; Shambaugh C; Zuo F; Galinski MS; Dubovsky F; ; Tang RS
    Vaccine; 2013 Jun; 31(26):2822-7. PubMed ID: 23602668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
    Nelson CL; Tang RS; Stillman EA
    Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
    Tang RS; Schickli JH; MacPhail M; Fernandes F; Bicha L; Spaete J; Fouchier RA; Osterhaus AD; Spaete R; Haller AA
    J Virol; 2003 Oct; 77(20):10819-28. PubMed ID: 14512532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
    Malkin E; Yogev R; Abughali N; Sliman J; Wang CK; Zuo F; Yang CF; Eickhoff M; Esser MT; Tang RS; Dubovsky F
    PLoS One; 2013; 8(10):e77104. PubMed ID: 24204744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
    Haller AA; Mitiku M; MacPhail M
    J Gen Virol; 2003 Aug; 84(Pt 8):2153-2162. PubMed ID: 12867647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
    Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
    J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
    Murphy BR; Collins PL
    Bull World Health Organ; 1997; 75(4):307-13. PubMed ID: 9342889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
    Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
    Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
    Murphy BR; Hall SL; Kulkarni AB; Crowe JE; Collins PL; Connors M; Karron RA; Chanock RM
    Virus Res; 1994 Apr; 32(1):13-36. PubMed ID: 8030364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.